Saturday, October 3, 2026

GBP/EUR Bearish Momentum: 0.81% Down In The Last 5 Sessions

ViaNews Editorial Team

August 30, 2023

GBP/EUR Bearish Momentum: 0.81% Down In The Last 5 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 0.81% for the last 5 sessions. At 02:06 EST on Wednesday, 30 August, GBP/EUR (GBPEUR) is $1.16.

GBP/EUR's yearly highs and lows, it's 7.399% up from its 52-week low and 1.342% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.21%, a positive 0.01%, and a positive 0.26%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.21% (last week), 0.23% (last month), and 0.26% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be overbought (>=80).

News about

  • Eur/usd price analysis: euro stays defensive above 1.0770 support ahead of German/us data. According to FXStreet on Tuesday, 29 August, "To sum up, EUR/USD buyers remain hopeful but the upside needs a strong fundamental push to cross the sturdy hurdles.", "It's worth noting that a convergence of the 10-DMA and a 13-day-long falling trend line guards immediate recovery of the EUR/USD pair near 1.0850."
  • Eur/usd price analysis: pair retraces recent losses, plods above 1.0800. According to FXStreet on Monday, 28 August, "A break above that level could support the EUR/USD pair to explore the area around the 14-day EMA at 1.0874 level, followed by the 1.0900 psychological level.", "The 14-day Relative Strength Index (RSI) remains below 50, which suggests a bearish bias of the EUR/USD traders. "
  • Eur/usd: euro bulls approach 1.0850 as US dollar traces softer yields, focus on German/us statistics. According to FXStreet on Monday, 28 August, "A convergence of the 13-day-old falling resistance line and the 10-day SMA, around 1.0850 by the press time, restricts the immediate upside of the EUR/USD pair even as the nearly oversold RSI conditions lure the buyers.", "Moving on, Germany's GfK Consumer Confidence Survey for September will become the immediate catalyst for the EUR/USD pair and may please the buyers in a case of matching the -24.3 expectations, versus -24.4 prior. "
  • Eur/usd price analysis: holds above the 1.0800 mark, upside seems limited. According to FXStreet on Tuesday, 29 August, " The immediate resistance level for EUR/USD appears at 1.0845-1.0850 region, representing a confluence of the 50-hour EMA and the upper boundary of the Bollinger Band. ", "Adding to this, the Relative Strength Index (RSI) remains below 50, supporting EUR/USD sellers for now. "
  • Eur/usd forex signal: bearish ahead of US consumer confidence data - 29 August 2023. According to DailyForex on Tuesday, 29 August, "Forex Brokers We Recommend in Your Region See full brokers list 1 Read full review Get Started BrokerGeoLists.push({type:'ReviewsNonPartner',id:'horizontal-top-5',size:5,fullReviewText:`Read full review`,getStartedText:`Get Started`,readReviewText:`Review`});Bearish viewSell the EUR/USD pair and set a take-profit at 1.0750.", "The EUR/USD exchange rate has been in a consolidation phase in the past two days and is hovering at the lowest level since June. "

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com